DE
DERM.US Journey Medical Corp
- Market cap
- USD 122M
- P/E
- -
- P/B
- 3.79x
- ROE
- -15.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DERM.US undervalued?
Graham numberThe Graham number of Journey Medical Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Journey Medical Corp fundamental analysis
No fundamental analysis for Journey Medical Corp yet.
Journey Medical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline …
Full company profileJourney Medical Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Journey Medical Corp annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 22.6M | 4.54M | 42.3M | 34.9M | 44.5M | 63.1M | 73.7M | 79.2M | 56.1M | 61.9M | 71.3M |
| Gross Profit | 22.6M | 4.54M | 41.2M | 24.4M | 29.9M | 31.1M | 42.9M | 52.5M | 35.3M | 36.7M | 27.3M |
| Operating Income | -90.6M | -300M | -214M | 5.26M | 7.85M | -34.9M | -27.5M | -2.07M | -13.7M | -8.17M | -2.09M |
| EBITDA | -87.4M | -295M | -206M | 6.52M | 9.37M | -32.8M | -23.2M | 1.92M | -8.40M | -3.33M | 2.62M |
| Net Income | -89.1M | -303M | -222M | 3.63M | 5.28M | -44.0M | -29.6M | -3.85M | -14.7M | -11.4M | -5.14M |
| EPS | -2.70 | -7.48 | -5.27 | 0.22 | 0.32 | -2.54 | -1.69 | -0.21 | -0.72 | -0.47 | -0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 313M | 561M | 344M | 33.9M | 51.9M | 97.3M | 105M | 76.8M | 80.2M | 94.6M | 104M |
| Total Liabilities | 65.2M | 411M | 353M | 31.1M | 41.6M | 55.2M | 88.2M | 56.5M | 60.2M | 62.7M | 71.6M |
| Shareholders' Equity | 247M | 150M | -9.04M | 2.75M | 10.3M | 42.0M | 17.0M | 20.4M | 20.1M | 31.9M | 32.2M |
| Cash & Short-term Investments | 252M | 551M | 313M | 4.80M | 8.25M | 49.1M | 32.0M | 27.4M | 20.3M | 24.1M | 22.3M |
| Total Debt | - | 279M | 314M | 5.30M | 9.92M | 9.05M | 23.0M | 17.7M | 25.7M | 25.4M | 25.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -74.1M | -104M | -213M | 9.02M | 5.13M | -2.18M | -13.5M | 5.24M | -9.13M | -12.4M | 2.35M |
| Capital Expenditure | 753K | 278K | 616K | 2.40M | 1.20M | 10.0M | 20.0M | 5.00M | 15.0M | 0.00 | 0.00 |
| Free Cash Flow | -74.9M | -104M | -214M | 6.62M | 3.93M | -12.2M | -33.5M | 240K | -24.1M | -12.4M | 2.35M |
| Ratios | |||||||||||
| ROE | -36.0% | -202.6% | - | 131.7% | 51.3% | -104.6% | -174.5% | -18.9% | -73.1% | -35.9% | -15.9% |
| ROA | -28.5% | -54.1% | -64.3% | 10.7% | 10.2% | -45.2% | -28.2% | -5.0% | -18.3% | -12.1% | -5.0% |
| Net Profit Margin | -394.4% | -6,678.3% | -523.3% | 10.4% | 11.9% | -69.7% | -40.2% | -4.9% | -26.1% | -18.5% | -7.2% |
| Debt to Equity | - | 1.87x | - | 1.93x | 0.96x | 0.22x | 1.35x | 0.87x | 1.28x | 0.80x | 0.79x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Journey Medical Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 371K | 0.02 | - |
| 2021 | USD 1.55M | 0.09 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Journey Medical Corp
- Insiders 32.46%
- Institutions 48.17%
- Public & others 19.38%
- Shares outstanding 22.2M
- Free float 15.6M
Top funds holding DERM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Wasatch Micro Cap | 1.25M | 4.42% | -9.96% | Sep 2026 |
| Wasatch Micro Cap Value | 720K | 2.55% | -11.60% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 470K | 1.67% | 0.00% | Sep 2026 |
| First Eagle Small Cap Opportunity I | 404K | 1.43% | +60.05% | Sep 2026 |
| Fidelity Extended Market Index | 82.9K | 0.29% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 42.4K | 0.15% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 41.3K | 0.15% | -0.05% | Sep 2026 |
| First Eagle US Small Cap Opp I-UC | 38.6K | 0.14% | +66.56% | Sep 2026 |
| Fidelity Series Total Market Index | 25.5K | 0.09% | 0.00% | Sep 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 15.9K | 0.06% | +1.92% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 14.1K | 0.05% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 10.4K | 0.04% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 7.38K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 4.64K | 0.02% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 3.13K | 0.01% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 3.00K | 0.01% | -11.33% | Sep 2026 |
| Victory Extended Market Index | 1.63K | 0.01% | +4.68% | Sep 2026 |
Top institutions holding DERM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Wasatch Advisors LP | 2.86M | 10.13% | +34.01% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1.61M | 5.70% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 675K | 2.39% | -37.60% | Jun 2026 |
| Punch & Associates Inv Mgmt Inc | 536K | 1.90% | 0.00% | Jun 2026 |
| Pale Fire Capital SE | 529K | 1.87% | +9.67% | Jun 2026 |
| Opaleye Management Inc | 350K | 1.24% | -63.54% | Jun 2026 |
| Summit Financial LLC | 347K | 1.23% | -8.70% | Jun 2026 |
| Jane Street Group LLC | 320K | 1.13% | 0.00% | Jun 2026 |
| Diametric Capital, LP | 296K | 1.05% | +50.53% | Jun 2026 |
| Ikarian Capital, LLC | 251K | 0.89% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 230K | 0.81% | -5.28% | Jun 2026 |
| Geode Capital Management, LLC | 216K | 0.77% | -53.37% | Jun 2026 |
| American Financial Group Inc | 180K | 0.64% | 0.00% | Jun 2026 |
| Trexquant Investment LP | 171K | 0.61% | +509.83% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 140K | 0.50% | 0.00% | Jun 2026 |
| J. Goldman & Co LP | 138K | 0.49% | -72.49% | Jun 2026 |
| Millennium Management LLC | 110K | 0.39% | -71.28% | Jun 2026 |
| BlackRock Inc | 101K | 0.36% | -89.62% | Jun 2026 |
| XTX Topco Ltd | 101K | 0.36% | +243.70% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 94.7K | 0.34% | -31.21% | Jun 2026 |
Journey Medical Corp company profile
- Company name
- Journey Medical Corp
- Ticker
- DERM.US
- Exchange
- USA Stocks
- Listed since
- Nov 12, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
- Fiscal year end
- December
- Address
- 9237 East Via de Ventura Blvd., Scottsdale, AZ, United States, 85258
- Phone
- 480 434 6670
- Website
- journeymedicalcorp.com
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Journey Medical Corp management
8- Dr. Lindsay Allan Rosenwald M.D.Executive Chairman · born 1955
- Mr. Claude MaraouiFounder, President, CEO & Director · born 1967
- Mr. Joseph M. BeneschCFO & Corporate Controller · born 1967
- Mr. Ramsey AlloushCOO, General Counsel & Company Secretary · born 1986
- Mr. Brian ProutExecutive Director of Marketing
- Mr. Robert NevinChief Commercial Officer · born 1969
- Jaclyn JaffeSenior Director of Corporate Operations
- Mr. Louis DonatiDirector of Market Access